EMEA-001214-PIP05-19

Key facts

Invented name
Fasenra
Active substance
benralizumab
Therapeutic area
Gastroentology-Hepatology
Decision number
P/0388/2021
PIP number
EMEA-001214-PIP05-19
Pharmaceutical form(s)
  • Solution for injection
  • Solution for injection/infusion
  • Age-appropriate dosage form for parenteral use
Condition(s) / indication(s)
Treatment of eosinophilic esophagitis
Route(s) of administration
  • Subcutaneous use
  • Intravenous use
Contact for public enquiries
AstraZeneca AB

E-mail: paediatrics@astrazeneca.com
Tel.  +46 855326000
 

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

Related content

How useful was this page?

Add your rating